Persistence of Biological Treatment and Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.

Study Overview
=================
Brief Summary
-----------------
One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb). These patients will be administered a series of medications and a follow-up will be carried out to analyze their evolution.

Detailed Description
-----------------
One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb). The drugs to be administered to patients are: JAK-type kinase inhibitors. Monoclonal antibodies against TNF. Soluble receptor against TNF. Biosimilar FAMEb. Rituximab. Abatacept. Drugs that block IL6. A follow-up will be carried out at 12, 24, 48, 60, 72 and 84 months from the start of treatment, to analyze how the patient's health improves.

Official Title
-----------------
Persistence of Biological Treatment and Inhibitors of Jak Kinases in Habitual Clinical Practice in Patients With Rheumatoid Arthritis. Influence of the Comorbidities.

Conditions
-----------------
Arthritis, Rheumatoid

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged ≥18 years. With a diagnosis of Adult Rheumatoid Arthritis according to the 2010 ACR / EULAR criteria. Who have received at least one of the doses of the study drugs. In follow-up in the consultations of the UGC of Rheumatology of the HUVM. With at least two complete evaluations (baseline and final) of clinical variables. Exclusion Criteria: Patients where the medical records lack sufficient baseline and final variables to perform the analysis. Patients in whom more than 50% of the variables to be collected are missing in the data collection.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cases 1<br>Patients treated with JAK-type kinase inhibitors. | |
| Cases 2<br>Patients treated with monoclonal antibodies against TNF. | |
| Cases 3<br>Patients treated with soluble receptor against TNF. | |
| Cases 4<br>Patients treated with FAME group biosimilars. | |
| Cases 5<br>Patients treated with rituximab. | |
| Cases 6<br>Patients treated with abatacept. | |
| Cases 7<br>Patients treated with drugs that block the IL6. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival study | To know the survival at 12, 24, 48, 60, 72 and 84 months to the synthetic directed anti-rheumatic drugs, disease modifiers (FAMEsd) and the biological disease modifying anti-rheumatic drugs (FAMEb) in patients with rheumatoid arthritis treated in routine. | Up to 60 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Study of clinical characteristics. | To know the sociodemographic and clinical characteristics of the patients who receive FAMEsd and FAMEb in routine clinical practice at the HUVM. | Up to 60 weeks | 
| Measure of the influence of comorbidities. | To assess the influence of comorbidities on drug persistence. | Up to 60 weeks | 
| Number of participants who discontinued treatment due to serious adverse effects. | Failure due to serious adverse events, adverse events of special interest, emerging adverse events and minor adverse events that require discontinuation of the drug. | Up to 60 weeks |